Detalhe da pesquisa
1.
Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728428
2.
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
Oncologist
; 27(2): 149-157, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641211
3.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Cytotherapy
; 24(7): 742-749, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219582
4.
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
Pediatr Blood Cancer
; 67(12): e28688, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32896942
5.
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
Qual Life Res
; 29(7): 1903-1911, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32100182
6.
A Bayesian approach in design and analysis of pediatric cancer clinical trials.
Pharm Stat
; 19(6): 814-826, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32537913
7.
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Oncologist
; 24(5): e180-e187, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30914464
8.
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Oncologist
; 22(5): 585-591, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28438889
9.
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
Clin Cancer Res
; 30(7): 1226-1231, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010220
10.
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Cancer Epidemiol Biomarkers Prev
; 32(6): 744-747, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012203
11.
Considerations for Drug Development in Myelodysplastic Syndromes.
Clin Cancer Res
; 29(14): 2573-2579, 2023 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36688922
12.
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
Clin Lymphoma Myeloma Leuk
; 23(6): 463-470.e1, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076368
13.
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
JAMA Oncol
; 9(2): 266-272, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580315
14.
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
Clin Cancer Res
; 29(12): 2179-2183, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36547666
15.
Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Ther Innov Regul Sci
; 57(4): 875-885, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072651
16.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084090
17.
Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic state.
Am J Pathol
; 178(6): 2931-7, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21550016
18.
Decoding kinase-adverse event associations for small molecule kinase inhibitors.
Nat Commun
; 13(1): 4349, 2022 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896580
19.
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Clin Cancer Res
; 28(16): 3411-3416, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435961
20.
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
Clin Cancer Res
; 28(14): 2989-2993, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325108